We are committed to Innovation
In addition to developing proprietary synthetic psilocybin formulations, we are pioneering novel drug discovery.
To improve patients' psychedelic experience, we are developing dosing and delivery methods for psychedelics.
The company is pursuing global patents at every opportunity, with a foundational provisional patent application already filed and many more on the way.
Latest Announcements
Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression
Read MoreWoke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief
Read MoreResearch & Development
Initial focus on psilocybin for depression based on evidence of efficacy. Proprietary formulations to enhance release profile of active drug and secure Intellectual Property
Partnerships with leading clinicians and formulation experts
The Market | Unmet Medical Need Continues to Grow
Over 700 million people are affected globally with some sort of mental illness, eg: depression, anxiety, PTSD, addiction or eating disorder
Source: The World Health Organisation
Global economic costs due to mental heath disorders estimated to be USD$800 Billion direct and US$1.7 Billion indirect
Source: National Centre for Biotechnology Information
1 IN 4 PEOPLE WILL SUFFER MENTAL HEALTH DISORDERS
25% of adults in the world will be affected by mental or neurological disorders at some point in their lives
Source: World Health Organisation
